Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Trial Summary
What is the purpose of this trial?
This study explores the role of T cells in monitoring disease status and response during anti-PD-1/PD-L1 treatment in patients with melanoma, lung and other cancer types. Measuring levels of specific targets such as Bim and soluble PD-L1 during therapy may help track treatment resistance and clinical outcomes. This information may also help researchers determine why some people with melanoma, lung and other cancer types respond to PD-1/PD-L1 treatment and others do not.
Research Team
Svetomir N. Markovic, MD, PhD
Principal Investigator
Mayo Clinic in Rochester
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Initial blood sample collection and baseline measurements for Bim levels and other markers
Monitoring
Ongoing blood sample collection and monitoring of T cell responses and resistance mechanisms during anti-PD-1 therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
National Cancer Institute (NCI)
Collaborator